# A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease

> **NCT00074984** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 82 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** Fabrazyme (agalsidase beta)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00074984
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2013-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074984, "A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00074984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*